tiprankstipranks
Advertisement
Advertisement
Marker Therapeutics Shareholders Approve Governance and Capital Changes
PremiumCompany AnnouncementsMarker Therapeutics Shareholders Approve Governance and Capital Changes
4M ago
Advancing Multi-Antigen Cell Therapies: Buy Rating on Marker Therapeutics Ahead of Key 2Q26 FDA Catalyst
Premium
Ratings
Advancing Multi-Antigen Cell Therapies: Buy Rating on Marker Therapeutics Ahead of Key 2Q26 FDA Catalyst
5M ago
Marker Therapeutics Highlights Strong MT-601 Data and Prepares for Key 2026 Milestones
Premium
Company Announcements
Marker Therapeutics Highlights Strong MT-601 Data and Prepares for Key 2026 Milestones
5M ago
Marker announces Baylor’s TACTOPS study featured on Good Morning America
PremiumThe FlyMarker announces Baylor’s TACTOPS study featured on Good Morning America
7M ago
Validating Marker Therapeutics’ MAR-T Platform in Pancreatic Cancer: MT-601 Upside Supports Buy Rating and $10 Target
Premium
Ratings
Validating Marker Therapeutics’ MAR-T Platform in Pancreatic Cancer: MT-601 Upside Supports Buy Rating and $10 Target
8M ago
Marker Therapeutics announces publication on MAR-T cells in pancreatic cancer
Premium
The Fly
Marker Therapeutics announces publication on MAR-T cells in pancreatic cancer
8M ago
Marker Therapeutics Strengthens Board with New Appointment
PremiumCompany AnnouncementsMarker Therapeutics Strengthens Board with New Appointment
10M ago
Marker Therapeutics appoints Penkus Corzo to board of directors
Premium
The Fly
Marker Therapeutics appoints Penkus Corzo to board of directors
10M ago
Marker Therapeutics’ Innovative Approach in AML and MDS Treatment: A Study Update
Premium
Company Announcements
Marker Therapeutics’ Innovative Approach in AML and MDS Treatment: A Study Update
10M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100